Access Pharmaceuticals.

The Cobalamin-based oral insulin product approval path is expected to be a 505 process. Boris Reznik, PhD, President and CEO of bioRASI commented, The program is a great fit for the features of both bioRASI and our established companions. .. Access Pharmaceuticals, bioRASI indication collaborative agreement to develop Cobalamin oral insulin product ACCESS PHARMACEUTICALS, INC. Under the contract, bioRASI will put into action the development program necessary to initiate the first-in-man research in Russia and satisfy all regulatory requirements through acceptance. While facilitating the studies and satisfying all required regulatory requirements for the program, bioRASI will also assist Access in finding partners for oral insulin and additional Cobalamin-based items in Russia and various other Eastern European and CIS countries.23andMe project aims at validating highly scalable pharmacogenomics research Objective is highly scalable pharmacogenomics study23andMe offers launched a task funded by the National Institutes of Wellness which is targeted at validating 23andMe’s highly-scalable system for pharmacogenomics research. The business received $190,000 in stimulus funding from the American Recovery and Reinvestment Take action of 2009 for ‘Web-centered Phenotyping for Genome-Wide Association Studies of Drug Response’ from NIH’s National Human Genome Analysis Institute.